TrovaGene is the developer of patented technology for the detection of transrenal DNA and RNA, short nucleic acid fragments, originating from normal and diseased cell death that cross the kidney barrier and can be detected in urine.  The company has … Continue reading →

Cel-Sci is focused on the research and development of improvements in the treatment of cancer and other diseases by utilizing the body’s immune system. Its lead investigational therapy, Multikine, is currently being studied in a pivotal global phase 3 clinical … Continue reading →

AtheroNova is an early-stage biotech company focused on the discovery, research, development and licensing of novel compounds designed to reduce or eliminate atherosclerotic plaque deposits. The company is currently completing two additional studies to validate the efficacy findings of its … Continue reading →

Chromadex is a natural products company that develops proprietary science-based solutions and ingredients applicable to the dietary supplement, food & beverage, cosmetic and pharmaceutical industries. The company markets and sells its products in the United States and Canada; and sells … Continue reading →

Spectrum Pharmaceuticals is a biotech company focused on the acquisition, development and commercialization of drug products, with a primary focus in oncology and hematology. The company markets three oncology drugs: FUSILEV®, for Injection in the U.S.; FOLOTYN®, also marketed in … Continue reading →

SciClone Pharmaceuticals, a U.S.-based, China-focused specialty pharmaceutical company, markets its product portfolio of differentiated therapies for oncology, infectious diseases and cardiovascular, urological, respiratory and central nervous system disorders. The company’s ZADAXIN® is approved in more than 30 countries for the … Continue reading →

Advanced Cell Technology is a biotech company that specializes in cellular technology in the field of regenerative medicine. The company has three cellular product platforms based on its stem cell technology: Retinal Pigment Epithelial (RPE) therapy for degenerative retinal disease; … Continue reading →

Neuralstem uses its patented technology to produce neural stem cells of the human brain and spinal cord. Neuralstem is in an FDA-approved phase I safety clinical trial for Lou Gehrig’s disease, and has been awarded orphan status designation by the … Continue reading →